Elsevier, a provider of scientific, technical and medical information products and services, has announced that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base – the Metabolizing Enzymes and Transporters Module.
The addition gives researchers a greater understanding and visibility of drug-drug interactions and their potential adverse reactions during critical stages of drug discovery and development.
The module will benefit researchers including toxicologists, pharmacokinetics researchers and departments, safety pharmacologists and clinical pharmacologists, who demand the highest quality data on preclinical and clinical metabolising enzymes and transporters. These researchers often struggle to find comparative data to understand how changes in the activity of metabolising enzymes and transporters affect the safety and efficacy of drugs. Currently, available information on DDIs is hard to collate and analyse and is not always normalised for comparison – making data analysis not only labour- and cost-intensive, but also open to critical error.
The Metabolizing Enzymes and Transporters Module allows for rapid, full text-search of literature from sources including approval documents from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), Elsevier says. It extracts both in vivo and in vitro human and animal experimental data on metabolising enzymes and transporters contained in preclinical and clinical studies, and applies it to the context of researchers’ experiments, facilitating efficient and diligent drug development.
'Identifying potential interactions that impact the efficacy and safety of a drug is a significant challenge,' said Philip MacLaughlin, director of product development at Elsevier. 'The new module supports early detection of viable drug candidates by providing the highest quality data and enabling comparative assessments of metabolising enzyme and transporter activities, reducing chances of unpredictable adverse reactions and even late stage clinical failures.'
